Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial
Academic Article
Publication Date:
2022
abstract:
The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle-invasive urothelial bladder carcinoma (MIBC). We herein present the survival outcomes after a median follow-up of three years.
Iris type:
1.1 Articolo in rivista
List of contributors:
Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A; Ross, Jeffrey S; Raggi, Daniele; Marandino, Laura; Costa de Padua, Tiago; Crupi, Emanuele; Colombo, Renzo; Colecchia, Maurizio; Lucianò, Roberta; Nocera, Luigi; Moschini, Marco; Briganti, Alberto; Montorsi, Francesco; Necchi, Andrea
Published in: